Paloma Partners Management Co Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA)

Paloma Partners Management Co reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 40.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,768 shares of the company’s stock after selling 3,289 shares during the quarter. Paloma Partners Management Co’s holdings in Moderna were worth $319,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Intrinsic Value Partners LLC increased its stake in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after buying an additional 24,505 shares during the period. Banco Santander S.A. purchased a new position in Moderna during the 3rd quarter valued at about $3,550,000. John G Ullman & Associates Inc. raised its holdings in shares of Moderna by 341.3% in the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after purchasing an additional 38,400 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after purchasing an additional 167,596 shares during the period. Finally, Vontobel Holding Ltd. boosted its stake in shares of Moderna by 148.2% during the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after purchasing an additional 69,313 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Up 3.1 %

Shares of MRNA stock opened at $42.94 on Friday. Moderna, Inc. has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The firm has a market capitalization of $16.52 billion, a PE ratio of -7.38 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The stock’s 50-day simple moving average is $50.69 and its 200-day simple moving average is $88.92.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the company earned ($1.39) EPS. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. Equities analysts expect that Moderna, Inc. will post -9.32 earnings per share for the current year.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 715 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,850 shares of company stock worth $134,560 over the last three months. Company insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Berenberg Bank began coverage on Moderna in a research note on Tuesday, November 19th. They set a “hold” rating and a $42.00 price objective for the company. Bank of America cut their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research note on Friday, September 13th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a report on Monday, November 18th. Finally, The Goldman Sachs Group cut their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $83.33.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.